Overexpression of EGFR has been implicated in pancreatic carcinoma aggressiveness and resistance to chemo- and radiation therapy.22,23 In a recent study by Morgan et al. 24, EGFR inhibitors cetuximab and erlotinib was used in combination with gemcitabine for enhanced efficacy against pancreatic cancer. Here, EGFR is linked to exocrine pancreatic carcinoma.